Welcome to our dedicated page for Elevance Health SEC filings (Ticker: ELV), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Elevance Health, Inc. (NYSE: ELV) SEC filings page on Stock Titan provides access to the company’s regulatory disclosures as filed with the U.S. Securities and Exchange Commission. Elevance Health operates in the direct health and medical insurance carriers industry and uses its SEC reports to present information on financial performance, capital structure, governance, and material events affecting its health benefits and Carelon segments.
Among the most important documents for ELV are its annual reports on Form 10-K and quarterly reports on Form 10-Q. These filings typically include detailed discussions of segment results for Health Benefits and Carelon, membership metrics across commercial, Medicare, Medicaid, and Federal Employee Program lines, risk factors, and management’s analysis of trends in benefit expense ratios, operating expenses, and cash flows. They also describe Elevance Health’s role as a licensee of Blue Cross Blue Shield plans in multiple states and its activities in pharmacy and healthcare services through Carelon.
Elevance Health also files current reports on Form 8-K to disclose specific material events. Recent 8-Ks have covered quarterly earnings releases, reaffirmation of earnings guidance and benefit expense ratio expectations, the election of independent directors to the board and their committee assignments, and a multi-tranche notes offering with maturities extending to 2055. These filings provide insight into governance practices, capital markets activity, and management’s public communications with investors.
Investors interested in executive and board matters can review proxy-related filings and 8-K disclosures regarding director appointments and compensation programs for non-employee directors. Those analyzing Elevance Health’s capital structure can examine registration statements and debt-related exhibits referenced in 8-K filings, which describe terms of senior notes, redemption provisions, and events of default.
On Stock Titan, ELV filings are updated in near real time as they appear in the SEC’s EDGAR system. AI-powered tools summarize lengthy documents such as 10-Ks and 10-Qs, highlight key metrics and risk discussions, and help users quickly locate information on topics like Medicare and Medicaid program exposure, pharmacy and services operations under Carelon, and guidance-related forward-looking statements. Users can also review Form 4 insider transaction reports when available to monitor trading activity by Elevance Health directors and officers.
By using this filings page, investors and researchers can navigate Elevance Health’s regulatory history more efficiently, compare disclosures across reporting periods, and better understand how the company presents its health benefits and services business to regulators and the market.
Elevance Health, Inc. furnished an update on its business by issuing a press release with financial results for the quarter ended September 30, 2025. The press release is attached as Exhibit 99.1 to an Item 2.02 Form 8-K dated October 21, 2025.
The company stated that the information in Item 2.02 and Exhibit 99.1 is being furnished, not filed, under the Exchange Act and is not incorporated by reference into Securities Act filings unless specifically referenced.
Mark Kaye, EVP & CFO of Elevance Health, Inc. (ELV), reported a sale of 2,895 shares of common stock on 10/02/2025 at a price of $340.24 per share. The filing states this disposition was a payment of tax liability by withholding stock related to the vesting of previously granted restricted stock. After the transaction, the reporting person beneficially owned 16,082 shares directly. The Form 4 was signed by an attorney-in-fact on 10/03/2025.
Elevance Health, Inc. completed a registered public offering of $750 million 4.000% notes due 2028, $750 million 4.600% notes due 2032, $1,000 million 5.000% notes due 2036 and $500 million 5.700% notes due 2055, all issued under its existing indenture with The Bank of New York Mellon Trust Company, N.A. as trustee.
The company received approximately $2,972.7 million in proceeds after underwriting discounts and expenses. It plans to use part of the cash to repay or redeem $400 million of 5.350% senior notes due 2025 and to redeem or repurchase $500 million of 4.900% senior notes due 2026, with the remainder earmarked for working capital and general corporate purposes, including acquisitions, other debt repayment and common stock repurchases.
The notes pay interest semi-annually on set dates beginning in 2026 and can be redeemed early at specified make-whole premiums before defined par call dates, or at 100% of principal plus accrued interest on or after those dates. If a change of control occurs and the notes are downgraded below investment grade by Moody’s Ratings, S&P Global Ratings and Fitch Ratings, Inc. within a specified period, holders must be offered 101% of principal plus accrued interest.
Erin M. Wessling, EVP & Chief Legal Officer of Elevance Health, Inc. (ELV), reported a transaction on 09/03/2025 in which 152 shares of Common Stock were disposed at a price of $321.59 per share. The Form 4 shows 5,020 shares remained beneficially owned after the reported transaction, held directly. The filing identifies the transaction code F and includes an explanation that the disposition was the payment of a tax liability by withholding stock incident to the vesting of previously granted restricted stock. The form was signed on behalf of the reporting person by Kathleen S. Kiefer on 09/05/2025.
Elevance Health director and EVP & Chief Legal Officer Erin M. Wessling filed an initial Form 3 disclosing direct beneficial ownership of 4,241 shares of common stock (restricted share units vesting 9/3/2025–3/3/2028) and two employee stock options covering 394 shares (exercise price $562.29) and 1,922 shares (exercise price $395.50). The filing notes a paper Form 3 was delivered 08/21/2025 because the reporting person's Form ID was pending.
Craig R. Ryan, Executive Vice President and Chief HR Officer of Elevance Health, Inc. (ELV), disclosed initial beneficial ownership in a Form 3 filed for the 08/11/2025 event date. He directly owns 4,383 shares of common stock, including 3,341 restricted stock units that vest between 02/01/2026 and 03/03/2028. He also holds two employee stock options: one for 965 shares exercisable beginning 03/01/2025 at $499.11 and one for 1,201 shares exercisable beginning 03/03/2026 at $395.50, both vesting in annual installments. The paper Form 3 was delivered 08/21/2025 due to a pending Form ID; an electronic filing followed when EDGAR access was available.
Erin M. Wessling, Executive Vice President and Chief Legal Officer of Elevance Health, acquired equity awards in the issuer. The Form 4 reports receipt of 931 restricted stock units at no cash cost and an employee stock option to purchase 3,541 shares at an exercise price of $322.33. The RSUs vest in three annual tranches (310, 310 and 311 shares) and the option vests in three annual installments (1,180; 1,180; 1,181 shares) beginning one year after grant, with the option exercisable through its stated expiration. The reported holdings after the transactions are 5,172 shares and 3,541 option shares, each held directly.
Craig Ryan R, EVP & Chief HR Officer of Elevance Health, Inc. (ELV), reported equity awards and an option grant on 09/02/2025. He was awarded 970 restricted share units (RSUs) with a $0 purchase price and now beneficially owns 5,353 shares. He also received an employee stock option with an exercise price of $322.33 for 3,690 shares, exercisable in three annual installments beginning 09/02/2026 and expiring 09/02/2035, leaving 3,690 underlying shares from the option. The RSUs vest in annual installments of 323, 323, and 324 shares on 9/2/2026, 9/2/2027 and 9/2/2028 respectively.
Elevance Health management expects to reaffirm full-year 2025 shareholders' earnings guidance of approximately $24.10 per diluted share, which includes about $5.90 per diluted share of net unfavorable items. Excluding those items, the Company expects adjusted shareholders' earnings of approximately $30.00 per diluted share.
The company also plans to reaffirm a full-year 2025 benefit expense ratio guidance of approximately 90.0%. Management cautions these expectations reflect current views of market, operational, regulatory and claim-cost assumptions and may change, and the filing includes standard forward-looking statement disclosures.
Susan D. DeVore, a director of Elevance Health, reported purchases of common stock totaling 1,200 shares on 08/19/2025 at a weighted average price of $312.15 per share. After these purchases she beneficially owned 3,502 shares directly. The filing specifies the purchases were executed in multiple trades at prices between $312.06 and $312.19, and the weighted average price is disclosed. The Form 4 was signed by an attorney-in-fact for the reporting person.